FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615661946> ?p ?o ?g. }

• W2615661946 endingPage "837" @default.
• W2615661946 startingPage "820" @default.
• W2615661946 abstract "Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder that affects genetically predisposed individuals. It manifests in susceptible individuals in response to exposure to Inhalant anesthetics, depolarizing muscle relaxants or extreme physical activity in hot environments. During exposure to these triggering agents, there is a rapid and sustained increase of myoplasmic calcium (Ca2+) concentration induced by hyperactivation of ryanodine receptor of skeletal muscle (RyR1), causing a profound change in Ca2+ homeostasis, featuring a hypermetabolic state. RyR1, Ca2+ release channels of sarcoplasmic reticulum, is the primary locus for MH susceptibility. Several mutations in the gene encoding the protein RyR1 have been identified; however, other genes may be involved. Actually, the standard method for diagnosing MH susceptibility is the muscle contracture test for exposure to halothane-caffeine (CHCT) and the only treatment is the use of dantrolene. However, with advances in molecular genetics, a full understanding of the disease etiology may be provided, favoring the development of an accurate diagnosis, less invasive, with DNA test, and also will provide the development of new therapeutic strategies for treatment of MH. Thus, this brief review aims to integrate molecular and clinical aspects of MH, gathering input for a better understanding of this channelopathy. A hipertermia maligna (HM) é uma doença farmacogenética potencialmente letal que acomete indivíduos geneticamente predispostos. Manifesta-se em indivíduos susceptíveis em resposta à exposição a anestésicos inalatórios, relaxantes musculares despolarizantes ou atividade física extrema em ambientes quentes. Durante a exposição a esses agentes desencadeadores, há um aumento rápido e sustentado da concentração de cálcio mioplasmático (Ca2+) induzido pela hiperativação dos receptores de rianodina (RYR1) do músculo esquelético, causando uma alteração profunda na homeostase de Ca2+, caracterizando um estado hipermetabólico. RYR1, canais de libertação de Ca2+ do retículo sarcoplasmático, é o principal local de susceptibilidade à HM. Várias mutações no gene que codifica a proteína RYR1 foram identificadas, mas outros genes podem estar envolvidos. Atualmente, o método padrão para o diagnóstico de sensibilidade à HM é o teste de contratura muscular para exposição ao halotano-cafeína (CHCT) e o único tratamento é o uso de dantroleno. No entanto, com os avanços no campo da genética molecular, um pleno entendimento da etiologia da doença pode ser fornecido, favorecendo o desenvolvimento de um diagnóstico preciso, menos invasivo, com o teste de ADN, e também proporcionar o desenvolvimento de novas estratégias terapêuticas para o tratamento da HM. Logo, esta breve revisão tem como objetivo integrar os aspectos clínicos e moleculares da HM, reunindo informações para uma melhor compreensão desta canalopatia. La hipertermia maligna (HM) es una enfermedad farmacogenética potencialmente letal que afecta a individuos genéticamente predispuestos. Se manifiesta en los individuos susceptibles en respuesta a la exposición a los anestésicos inhalatorios, relajantes musculares despolarizantes o actividad física extrema en ambientes calientes. Durante la exposición a esos agentes desencadenantes, existe un aumento rápido y constante de la concentración de calcio mioplasmático (Ca2+) inducido por la hiperactivación de los receptores de rianodina (RYR1) del músculo esquelético, causando una alteración profunda en la homeostasa de Ca2+, y caracterizando un estado hipermetabólico. RYR1, canales de liberación de Ca2+ del retículo sarcoplasmático, es la principal región de susceptibilidad a la HM. Varias mutaciones en el gen que codifica la proteína RYR1 han sido identificadas, pero otros genes pueden estar involucrados también. Actualmente, el método estándar para el diagnóstico de la sensibilidad a la HM es el test de contractura muscular para la exposición al halotano-cafeína (CHCT) y el único tratamiento es el uso de dantroleno. Sin embargo, con los avances en el campo de la genética molecular, un pleno entendimiento de la etiología de la enfermedad puede ser suministrado, favoreciendo así el desarrollo de un diagnóstico preciso, menos invasivo, con el test de ADN, y también proporcionar el desarrollo de nuevas estrategias terapéuticas para el tratamiento de la HM. Por eso, esta breve revisión intenta integrar los aspectos clínicos y moleculares de la HM, reuniendo informaciones para lograr una mejor comprensión de esa canalopatía." @default.
• W2615661946 created "2017-05-26" @default.
• W2615661946 creator A5000621927 @default.
• W2615661946 creator A5025291127 @default.
• W2615661946 creator A5067816136 @default.
• W2615661946 date "2012-11-01" @default.
• W2615661946 modified "2023-09-25" @default.
• W2615661946 title "Malignant Hyperthermia: Clinical and Molecular Aspects" @default.
• W2615661946 cites W1525891657 @default.
• W2615661946 cites W1963480642 @default.
• W2615661946 cites W1964139613 @default.
• W2615661946 cites W1964597849 @default.
• W2615661946 cites W1980015500 @default.
• W2615661946 cites W1983346776 @default.
• W2615661946 cites W1993430736 @default.
• W2615661946 cites W2009294542 @default.
• W2615661946 cites W2010877490 @default.
• W2615661946 cites W2017829107 @default.
• W2615661946 cites W2031377102 @default.
• W2615661946 cites W2031857555 @default.
• W2615661946 cites W2034068474 @default.
• W2615661946 cites W2038013299 @default.
• W2615661946 cites W2038560331 @default.
• W2615661946 cites W2039547987 @default.
• W2615661946 cites W2043390438 @default.
• W2615661946 cites W2044219698 @default.
• W2615661946 cites W2045954062 @default.
• W2615661946 cites W2049312403 @default.
• W2615661946 cites W2049876060 @default.
• W2615661946 cites W2050824263 @default.
• W2615661946 cites W2066537890 @default.
• W2615661946 cites W2074201509 @default.
• W2615661946 cites W2083049504 @default.
• W2615661946 cites W2086449013 @default.
• W2615661946 cites W2092955743 @default.
• W2615661946 cites W2103290447 @default.
• W2615661946 cites W2104746669 @default.
• W2615661946 cites W2115263783 @default.
• W2615661946 cites W2133300050 @default.
• W2615661946 cites W2136285855 @default.
• W2615661946 cites W2137283585 @default.
• W2615661946 cites W2141630881 @default.
• W2615661946 cites W2148269081 @default.
• W2615661946 cites W2155842024 @default.
• W2615661946 cites W4236213427 @default.
• W2615661946 cites W4243286667 @default.
• W2615661946 cites W4251590142 @default.
• W2615661946 cites W4323874117 @default.
• W2615661946 doi "https://doi.org/10.1016/s0034-7094(12)70182-4" @default.
• W2615661946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23176990" @default.
• W2615661946 hasPublicationYear "2012" @default.
• W2615661946 type Work @default.
• W2615661946 sameAs 2615661946 @default.
• W2615661946 citedByCount "25" @default.
• W2615661946 countsByYear W26156619462013 @default.
• W2615661946 countsByYear W26156619462014 @default.
• W2615661946 countsByYear W26156619462015 @default.
• W2615661946 countsByYear W26156619462016 @default.
• W2615661946 countsByYear W26156619462017 @default.
• W2615661946 countsByYear W26156619462018 @default.
• W2615661946 countsByYear W26156619462020 @default.
• W2615661946 countsByYear W26156619462021 @default.
• W2615661946 countsByYear W26156619462022 @default.
• W2615661946 countsByYear W26156619462023 @default.
• W2615661946 crossrefType "journal-article" @default.
• W2615661946 hasAuthorship W2615661946A5000621927 @default.
• W2615661946 hasAuthorship W2615661946A5025291127 @default.
• W2615661946 hasAuthorship W2615661946A5067816136 @default.
• W2615661946 hasBestOaLocation W26156619461 @default.
• W2615661946 hasConcept C113217602 @default.
• W2615661946 hasConcept C126322002 @default.
• W2615661946 hasConcept C2776333580 @default.
• W2615661946 hasConcept C2778575482 @default.
• W2615661946 hasConcept C2779959927 @default.
• W2615661946 hasConcept C2781460320 @default.
• W2615661946 hasConcept C42219234 @default.
• W2615661946 hasConcept C519063684 @default.
• W2615661946 hasConcept C60644358 @default.
• W2615661946 hasConcept C71924100 @default.
• W2615661946 hasConcept C86803240 @default.
• W2615661946 hasConcept C98274493 @default.
• W2615661946 hasConceptScore W2615661946C113217602 @default.
• W2615661946 hasConceptScore W2615661946C126322002 @default.
• W2615661946 hasConceptScore W2615661946C2776333580 @default.
• W2615661946 hasConceptScore W2615661946C2778575482 @default.
• W2615661946 hasConceptScore W2615661946C2779959927 @default.
• W2615661946 hasConceptScore W2615661946C2781460320 @default.
• W2615661946 hasConceptScore W2615661946C42219234 @default.
• W2615661946 hasConceptScore W2615661946C519063684 @default.
• W2615661946 hasConceptScore W2615661946C60644358 @default.
• W2615661946 hasConceptScore W2615661946C71924100 @default.
• W2615661946 hasConceptScore W2615661946C86803240 @default.
• W2615661946 hasConceptScore W2615661946C98274493 @default.
• W2615661946 hasIssue "6" @default.
• W2615661946 hasLocation W26156619461 @default.
• W2615661946 hasLocation W26156619462 @default.
• W2615661946 hasOpenAccess W2615661946 @default.
• W2615661946 hasPrimaryLocation W26156619461 @default.

• next